Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 12/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CLK2 | P49760 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3486573 | 0.88 | MAP3K5 (0.50) | MAP3K5GAALMNAMAPTKDM4E | |
| SCHEMBL3486502 | 0.82 | MAP3K5 (0.66) | MAP3K5CLK2 | |
| SCHEMBL3485303 | 0.81 | MAP3K5 (0.67) | MAP3K5GAALMNAMAPTKDM4E | |
| Hydrochloric Acid SCHEMBL3486394 | 0.80 | MAP3K5 (0.66) | MAP3K5GAALMNAMAPTKDM4E | |
| SCHEMBL3485759 | 0.80 | MAP3K5 (0.66) | MAP3K5CLK2 | |
| SCHEMBL3486579 | 0.80 | CLK2 (0.63) | MAP3K5CLK2 | |
| SCHEMBL3485827 | 0.79 | MAP3K5 (0.55) | MAP3K5GAALMNAMAPTKDM4E | |
| SCHEMBL3485464 | 0.78 | MAP3K5 (0.57) | MAP3K5GAALMNAMAPTKDM4E | |
| SCHEMBL3486289 | 0.72 | MAP3K5 (0.69) | MAP3K5CLK2 | |
| SCHEMBL3486385 | 0.70 | POLB (0.44) | LMNAMAPTBLMTDP1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12408914-B2 | Systems and methods for customizing mechanical strength in stimuli-responsive bioabsorbable materials | CILAG GMBH INTERNATIONAL (CH) | 2025-09-09 | — | — | US | disclosed |
| EP-4543502-A1 | SYSTEMS AND METHODS FOR CUSTOMIZING MECHANICAL STRENGTH IN STIMULI-RESPONSIVE BIOABSORBABLE MATERIALS | Cilag GmbH International (CH) | 2025-04-30 | — | — | EP | disclosed |
| US-20240423617-A1 | SYSTEMS AND METHODS FOR CUSTOMIZING MECHANICAL STRENGTH IN STIMULI-RESPONSIVE BIOABSORBABLE MATERIALS | CILAG GMBH INTERNATIONAL (CH) | 2024-12-26 | — | — | US | disclosed |
| WO-2024261659-A1 | SYSTEMS AND METHODS FOR CUSTOMIZING MECHANICAL STRENGTH IN STIMULI-RESPONSIVE BIOABSORBABLE MATERIALS | CILAG GMBH INTERNATIONAL (CH) | 2024-12-26 | — | — | WO | disclosed |
| US-20240423620-A1 | COMPRESSIBLE SURGICAL ADJUNCTS, CARTRIDGES, AND CARTRIDGE ASSEMBLIES AND METHODS OF MAKING SURGICAL ADJUNCTS | CILAG GMBH INTERNATIONAL (CH) | 2024-12-26 | — | — | US | disclosed |
| EP-3293200-B1 | METHOD FOR ENGINEERING IMMUNOGLOBULINS | F STAR THERAPEUTICS LTD (GB) | 2024-01-03 | — | — | EP | disclosed |
| US-20210388339-A1 | METHOD FOR ENGINEERING IMMUNOGLOBULINS | F-STAR THERAPEUTICS LIMITED (GB) | 2021-12-16 | — | — | US | disclosed |
| EP-3293200-A1 | METHOD FOR ENGINEERING IMMUNOGLOBULINS | F-Star Biotechnologische Forschungs- und Entwicklungsges.m.b.H (AT) | 2018-03-14 | — | — | EP | disclosed |
| US-20170369868-A1 | METHOD FOR ENGINEERING IMMUNOGLOBULINS | F-STAR BIOTECHNOLOGISCHE FORSCHUNGS- UND ENTWICKLUNGSGES.M.B.H. (AT) | 2017-12-28 | — | — | US | disclosed |
| EP-2044117-B1 | METHOD FOR ENGINEERING IMMUNOGLOBULINS | F-STAR BIOTECHNOLOGISCHE FORSCHUNGS- UND ENTW M B H (AT) | 2017-09-06 | — | — | EP | disclosed |
| US-20070065415-A1 | Compositions and methods for the augmentation and repair of defects in tissue | DASK TECHNOLOGIES, LLC | 2007-03-22 | — | — | US | disclosed |
| EP-0592106-B1 | Resurfacing of rodent antibodies | IMMUNOGEN INC (US) | 2004-11-24 | — | — | EP | disclosed |
| US-5663069-A | PROTEINS AS TARGET MOLECULES WITH HISTIDINE, CYSTEINE, TYROSINE AND TRYPTOPHAN | MEDICAL SCIENCE PARTNERS (US) | 1997-09-02 | — | — | US | disclosed |
| US-5650267-A | PROTEINS, POLYPEPTIDES, NUCLEIC ACIDS AND PLASMIDS DETECTED IN SOLUTIONS | SYMBIOTECH, INC. (US) | 1997-07-22 | — | — | US | disclosed |
| US-5646030-A | CULTURING OF AUXOTROPHIC PRETREATED STARTER AND FEEDER CELLS IN PRESENCE OF LAMBDOID BACTERIOPHAGE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1997-07-08 | — | — | US | disclosed |
| EP-0760012-A4 | METHOD OF DETECTING COMPOUNDS UTILIZING GENETICALLY MODIFIED LAMBDOID BACTERIOPHAGE | SYMBIOTECH INC (US) | 1997-07-02 | — | — | EP | disclosed |
| EP-0760012-A1 | METHOD OF DETECTING COMPOUNDS UTILIZING GENETICALLY MODIFIED LAMBDOID BACTERIOPHAGE | SYMBIOTECH, INC. (US) | 1997-03-05 | — | — | EP | disclosed |
| WO-1996006164-A1 | METHOD FOR ISOLATING MUTANT CELLS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1996-02-29 | — | — | WO | disclosed |
| WO-1995034683-A1 | METHOD OF DETECTING COMPOUNDS UTILIZING GENETICALLY MODIFIED LAMBDOID BACTERIOPHAGE | SYMBIOTECH, INC. (US) | 1995-12-21 | — | — | WO | disclosed |
| EP-0592106-A1 | Resurfacing of rodent antibodies | IMMUNOGEN INC (US) | 1994-04-13 | — | — | EP | disclosed |